 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H23N3O |
| Molar mass | 357.5 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MN 18 is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1][2] It is the indazole analogue of NNE1.
Legal status
MN-18 is banned in Sweden.[3]
See also
References
- ^ "MN-18". Southern Association of Forensic Scientists. Retrieved 23 July 2015.
- ^ Nahoko Uchiyama, Yoshihiko Shimokawa, Ruri Kikura-Hanajiri, Yosuke Demizu, Yukihiro Goda, Takashi Hakamatsuka (February 2015). "A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N–OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products". Forensic Toxicology. doi:10.1007/s11419-015-0268-7.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "Cannabinoider föreslås bli klassificerade som hälsofarlig vara". Folkhälsomyndigheten. 28 May 2014. Retrieved 23 July 2015.